Monthly Archives: September 2015

Shire v. Amneal Pharma – Adjusting the Rearview Mirror

While the IP law world is being rocked by new developments in biosimilars, patent-eligible subject matter and IPR’s, it is almost refreshing to see a decision upholding the validity of claims to a “small molecule” drug based on application of … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , | 1 Comment

25 Critical Patentability & Validity Developments

The Chisum Patent Academy is pleased to announce the September 2015 publication by Wolters Kluwer Law & Business of the annual Update for Volume I (Patentability and Validity) of the practitioner treatise, Mueller on Patent Law, authored by our co-founder, … Continue reading

Posted in Miscellaneous | Tagged , , , , , | Leave a comment

PTO Announces Requirements for Expedited Appeals for Small Entities

For some years, I have complained that the lack of a timely appeal process to the Board (“PTAB”) effectively removes the appeal process as a prosecution tool. The average pendency of an appeal to the Board from a rejection arising … Continue reading

Posted in Appeals, Patent Reform Legislation, s.102 | Tagged , | Leave a comment

Sandoz Launches First Biosimilar Drug in U.S.

A new chapter in the generics/innovator wars began Thursday as Sandoz, Novartis’ generics division launched its Neupogen biosimilar, Zarxio, in the U.S. at about a 15-30% discount from the price of Neupogen. While biosimilars have been marketed in Europe since 2006, Congress … Continue reading

Posted in Biosimilars | Tagged , , , , , , , , , , , | Leave a comment